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Abstract
Background: The accessory gene regulator (agr) and staphylococcal accessory regulator (sarA) play opposing roles in
Staphylococcus aureus biofilm formation. There is mounting evidence to suggest that these opposing roles are
therapeutically relevant in that mutation of agr results in increased biofilm formation and decreased antibiotic susceptibility
while mutation of sarA has the opposite effect. To the extent that induction of agr or inhibition of sarA could potentially be
used to limit biofilm formation, this makes it important to understand the epistatic relationships between these two loci.
Methodology/Principal Findings: Wegenerated isogenic sarA andagr mutantsinclinical isolatesofS. aureus a n da s s e s s e dt h e
relative impactonbiofilmformation. Mutationofagr resulted inanincreased capacitytoforma biofilmin the 8325-4laboratory
strain RN6390 but had little impact in clinical isolates S. aureus. In contrast, mutation of sarA resulted in a reduced capacity to
form a biofilm in all clinical isolates irrespective of the functional status of agr. This suggests that the regulatory role of sarA in
biofilm formation is independent of the interaction between sarA and agr and that sarA is epistatic to agr in this context. This
was confirmed by demonstrating that restoration of sarA function restored the ability to form a biofilm even in the
corresponding agr mutants. Mutation of sarA in clinical isolates also resulted in increased production of extracellular proteases
and extracellular nucleases, both of which contributed to the biofilm-deficient phenotype of sarA mutants. However, studies
comparingdifferentstrainswithandwithoutproteasesinhibitorsand/ormutationofthenucleasegenesdemonstratedthatthe
agr-independent, sarA-mediated repression of extracellular proteases plays a primary role in this regard.
Conclusions and Significance: The results we report suggest that inhibitors of sarA-mediated regulation could be used to
limit biofilm formation in S. aureus and that the efficacy of such inhibitors would not be limited by spontaneous mutation of
agr in the human host.
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Introduction
Biofilm formation is an important aspect of many Staphylococcus
aureus infections including endocarditis, osteomyelitis, and infec-
tions of implanted medical devices. This is true not only with
respect to the pathogenesis of the infection itself but also with
respect to antimicrobial therapy. Indeed, the presence of a biofilm
limits the efficacy of antimicrobial therapy to the point that
surgical intervention is often required to remove infected tissues
and/or implanted devices [1]. For this reason, a considerable
research effort has been aimed at defining the mechanistic basis of
S. aureus biofilm formation. These studies have focused on the role
of both individual components and the regulatory factors that
modulate the production of these components. To date, over 20
genes have been implicated, with approximately half of these
serving a regulatory role [2]. We chose to focus on the accessory
gene regulator (agr) and the staphylococcal accessory regulator
(sarA) because both of these loci have been shown to play central
roles in S. aureus regulatory circuits that includes important but
generally opposing roles in biofilm formation. Specifically, while
there is one report to the contrary [3], most studies have
concluded that expression of agr limits biofilm formation [4–6],
and it has been suggested that this may serve as a means for the
dispersal of S. aureus from an established biofilm [7–9]. In contrast,
expression of sarA has consistently been shown to promote biofilm
formation in both S. aureus and S. epidermidis [4–6,10,11].
There are also reports demonstrating that the opposing roles of
sarA and agr in biofilm formation are therapeutically relevant. For
instance, we demonstrated that mutation of sarA can be correlated
with increased susceptibility to the functionally-diverse antibiotics
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established biofilm [12,13]. At least under in vitro conditions, this
increased susceptibility was evident even after taking into account
the reduced capacity of a sarA mutant to form a biofilm [12]. In
contrast, induction of agr expression was shown to result in the
detachment of S. aureus cells from an established biofilm resulting
in increased susceptibility to diverse antibiotics including rifampi-
cin and levofloxacin [7,8,14]. Other reports have demonstrated
that agr mutants accumulate within a biofilm and ultimately
become the predominant subpopulation [6]. There is also a report
demonstrating that the loss of agr function may confer a selective
advantage in vivo, particularly under the pressure of vancomycin
therapy [15]. Taken together, these results suggest that the
opposing roles of sarA and agr in biofilm formation can be directly
correlated with antibiotic susceptibility, with expression of the first
leading to biofilm-associated intrinsic resistance and expression of
the second having the opposite effect. This makes it important to
define the epistatic relationships between sarA and agr in the
context of biofilm formation.
Because both sarA and agr play global regulatory roles in S. aureus
[16–18], it is not obvious why either would have an impact on
biofilm formation. Moreover, expression of sarA is generally
associated with increased expression of agr [16,19–21], and based
on this it might be anticipated that these two loci would play
consistent rather than opposing roles with respect to each other.
However, sarA also modulates expression of many genes
independently of agr, examples of which include the genes
encoding extracellular proteases and nucleases [22,23]. Specifi-
cally, mutation of agr results in reduced production of these
enzymes while mutation of sarA has the opposite effect [17,23,24].
Additionally, extracellular DNA (eDNA) has been shown to
contribute to biofilm formation in S. aureus [25], and limiting
nuclease or protease production by mutagenesis or the use of
inhibitors of protease activity has been shown to promote biofilm
formation and to partially restore biofilm formation in a sarA
mutant [8,14,23,26].
Collectively, these studies suggest that the opposing roles of agr
and sarA in biofilm formation are due to the fact that the first
induces while the second represses the production of extracellular
proteases and/or nucleases. This is consistent with our results
comparing the clinical isolate UAMS-1 with the commonly-
studied 8325-4 laboratory strain RN6390. Specifically, by
comparison to RN6390, UAMS-1 expresses agr at much lower
levels, produces reduced amounts of extracellular proteases, and
forms a more robust biofilm [10,24,27]. Additionally, mutation of
agr enhances biofilm formation in RN6390 but has little impact in
UAMS-1 and, conversely, mutation of sarA results in increased
protease production and decreased biofilm formation in UAMS-1
but has little impact in RN6390 [10]. All S. aureus strains derived
from 8325, including the 8325-4 strain RN6390, have genetic
defects that have been shown to contribute to its high level of agr
expression [28–30], and restoration of the rsbU defect in RN6390
has been correlated with decreased expression of agr, decreased
production of extracellular proteases, and an increased capacity to
form a biofilm [8–29]. However, community-acquired, methicil-
lin-resistant S. aureus (CA-MRSA) isolates of the USA300 clonal
lineage, which are increasingly prominent worldwide [31], are
closely related to 8325-derived strains and also express agr at high
levels [17,32,33]. As a result, they produce extracellular toxins at
high levels [34], and this contributes to their ability to cause
invasive disease even in otherwise healthy individuals [35,36].
The production of extracellular proteases is also under the
regulatory control of agr, and this suggests that the increased toxin
production in USA300 isolates would be correlated with increased
protease production and may therefore come at the expense of the
ability to form a biofilm. Support for this hypothesis comes from a
recent report demonstrating that mutation of agr, the inclusion of
inhibitors of extracellular protease activity, and the mutation of
specific genes encoding extracellular proteases can all be
correlated with an enhanced capacity to form a biofilm in the
USA300 isolate LAC [7,8,14]. However, to date, this issue has not
been examined in a comprehensive manner, and it remains
unclear whether expression of agr has a significant impact on
biofilm formation in USA300 isolates in general and, if so, whether
this limits the regulatory role of sarA in this respect. Based on this,
we examined the impact of sarA and agr on biofilm formation in
diverse clinical isolates with a specific emphasis on CA-MRSA
isolates of the USA300 clonal lineage.
Results and Discussion
The impact of agr on biofilm formation
We previously demonstrated that clinical isolates of S. aureus
generally form a more robust biofilm than the 8325-4 laboratory
strain RN6390 and that biofilm formation in the latter is enhanced
by mutation of agr [10]. This suggests that the level of agr
expression in RN6390 can be functionally defined as excessive at
least in the context of biofilm formation. The fact that clinical
isolates of the USA300 clonal lineage are genotypically related to
isolates of the 8325 lineage [32] and also express agr at high levels
[8] led us to question whether they might also have a reduced
capacity to form a biofilm and, if so, whether this could also be
overcome by mutation of agr. To examine this issue, we chose
three USA300 isolates, the genomes of two of which (FPR3757
and TCH1516, designated here as UAMS-1782 and UAMS-
1790) have been sequenced [32,37] while the third (UAMS-1625)
was isolated from a patient with a fatal brain abscess [38].
The levels of RNAIII produced by each strain were dependent
on both growth phase and growth medium. RNAIII levels were
higher in TSB than in biofilm medium (BM) in all strains except
RN6390, which produced comparable levels of RNAIII whether
grown in BM or TSB (Fig. 1). The reduced production of RNAIII
in BM is consistent with reports demonstrating that RNAIII
production is repressed in medium supplemented with glucose
[7,24]. Nevertheless, all clinical isolates produced RNAIII in the
expected growth-phase dependent pattern when grown in BM in
that, by comparison to exponential growth, the production of
RNAIII was increased in all strains in the post-exponential growth
phase while, by comparison to the post-exponential growth phase,
RNAIII levels were decreased in all strains in stationary-phase
cultures (Fig. 1). RN6390 was once again an exception in that the
levels of RNAIII observed in this strain were generally consistent
across all growth phases.
Of the planktonic growth conditions examined in this report,
the most applicable by comparison to our biofilm assays is a
stationary-phase culture in biofilm medium, and under these
conditions the targeted strains could be divided into three groups.
The first consisted solely of RN6390, which produced higher levels
of RNAIII by comparison to all other strains. The second
consisted of the USA300 isolates UAMS-1782 and UAMS-1790,
both of which produced RNAIII at levels that exceeded those
observed in UAMS-1 or the USA300 isolate UAMS-1625 to a
statistically-significant degree (Fig. 1). These results demonstrate
that, while USA300 isolates generally produced RNAIII at levels
that exceeded those observed in UAMS-1, they were nevertheless
below those observed in RN6390. More importantly, this
difference appears to be biologically relevant in that, as defined
by our microtiter plate assay, all USA300 isolates formed a biofilm
sarA and agr in Biofilms
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significantly greater than that observed with RN6390 (Fig. 2).
The fact that all three USA300 isolates formed a biofilm in our
assay is in contrast to an earlier report demonstrating that the
USA300 isolate LAC did not form a biofilm in a microtiter plate
assay [8]. Because we did not include LAC in our experiments,
one possible explanation for this difference is strain-dependent
variability even among USA300 isolates. However, this seems
unlikely in that one of the USA300 isolates we included (UAMS-
1782) is essentially indistinguishable from LAC as defined by both
genotypic and phenotypic characteristics [39]. An alternative
explanation is that we employed a different growth medium in our
microtiter plate assay and, unlike the earlier study [8], coated the
substrate with human plasma. With regard to the first, one possible
explanation for our disparate results is that expression of agr was
reduced in USA300 isolates under our growth conditions to the
point that it had no impact on biofilm formation. To the extent
that RNAIII levels remained relatively high in RN6390 even
under these conditions, this is consistent with the observation that
RN6390 was the only strain we examined in which mutation of agr
had an impact on biofilm formation (see below).
Coating with plasma was also shown to play an important role.
Specifically, we repeated our experiments using the same
microtiter plate assay but without plasma coating and found that,
as with the other clinical isolates we have examined [10], plasma
coating enhanced biofilm formation in all USA300 isolates (Fig. 3).
Thus, it seems likely that our use of supplemented TSB as a
growth medium and plasma coating of the substrate both
contributed to the ability of USA300 isolates to form a biofilm
in our assay. While it is difficult to correlate in vitro results using any
assay conditions with in vivo conditions, implanted medical devices
are coated with plasma proteins in vivo [40–43]. Moreover, the
results we have observed with our microtiter plate biofilm assay
have in all cases been consistent with those obtained using a
murine model of catheter-associated biofilm formation
[13,23,25,44]. This includes experiments done with the USA300
isolate UAMS-1625. Specifically, while we found that this strain
had a reduced capacity to form a biofilm in vivo by comparison to
UAMS-1, it was nevertheless capable of doing so to an extent that
could be correlated with reduced antibiotic susceptibility [13]. We
also confirmed the negative impact of mutating sarA on biofilm
formation, and the positive impact of this on antibiotic
susceptibility, in both UAMS-1 and UAMS-1625 under both in
vitro and in vivo conditions [12,13].
We also found that mutation of agr did not enhance biofilm
formation in any of the USA300 isolates irrespective of whether
plasma coating was employed (Fig. 4) and this is consistent with
the results of Lauderdale et al. [8] who found that mutation of agr
in LAC had little impact on biofilm formation as assessed using
flow cells. However, this certainly does not preclude an important
role for agr in S. aureus biofilm formation, particularly given the
relatively low levels of RNAIII production observed in USA300
isolates under our biofilm growth conditions. For instance, O’Neill
Figure 2. Biofilm formation in isolates of the USA300 clonal
lineage. Biofilm formation was assessed using a microtiter plate assay
as previously described [10]. Results are shown as the mean 6 the
standard deviation of 6 replicate samples from each strain. Statistical
analysis confirmed a significant difference between RN6390 and each of
the other strains.
doi:10.1371/journal.pone.0010790.g002
Figure1.Productionof RNAIII as afunctionof strain, growth phase,andgrowth medium. RNA was extracted from each strain grown in biofilm
medium (BM) during the exponential (E, OD560=1.0), post-exponential growth phase (PE, OD560=3.0) and stationary (S) phases and the amount of RNAIII
determined by qRT-PCR. RNA was also isolated from stationary-phase cultures grown in TSB. The value observed with UAMS-1 during the exponential
growthphasewasset at1.0withtheresultsobservedforotherstrainsshownrelativetothisvalue.Resultsareshownas themean6thestandarddeviation
oftriplicatesamples.Statisticalanalysisoftheresultsobservedinstationary-phasesamplesgrowninBMconfirmedasignificantdifferencebetween RN6390
and all other strains and between UAMS-1782 and UAMS-1790 by comparison to both UAMS-1 and UAMS-1625.
doi:10.1371/journal.pone.0010790.g001
sarA and agr in Biofilms
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formation in 5 of 13 methicillin-resistant clinical isolates even
when the medium was supplemented with glucose to a degree that
has been associated with reduced expression of agr [7].
Additionally, mutation of sigB in LAC limited biofilm formation
even in flow cells, and concomitant mutation of agr reversed this
effect [8].
The impact of sarA on biofilm formation and its
relationship to the production of extracellular proteases
Unlike agr, mutation of sarA was found to limit biofilm formation
in all USA300 isolates irrespective of the functional status of agr
(Fig. 4). O’Neill et al. [45] also found that mutation of sarA
inhibited biofilm formation in all strains but suggested that this
involved two different mechanisms, with the negative impact of
mutating sarA in methicillin-sensitive strains being due primarily to
the decreased expression of the ica operon leading to reduced
production of the polysaccharide intracellular adhesin (PIA) while
in methicillin-resistant strains the more important consideration
was the impact of sarA on the production of surface-associated
protein adhesins. We previously demonstrated that mutation of
sarA in the methicillin-sensitive strain UAMS-1 does result in
reduced PIA production, but an isogenic ica mutant retained the
capacity to form a biofilm [27]. This demonstrates that decreased
PIA production cannot account for the biofilm-deficient pheno-
type of a UAMS-1 sarA mutant. Rather, our results to date suggest
that the more important consideration even in UAMS-1 is the
increased production of extracellular proteases [23].
Production of these proteases has a negative impact on the
presence of several surface-associated adhesins. These include the
fibronectin-binding proteins (FnbA and FnbB) and protein A
[24,46], both of which contribute to biofilm formation in at least
some clinical isolates of S. aureus [45,47,48]. Additionally,
expression of agr both represses the production of these adhesins
and induces the production of extracellular proteases [21,49],
either or both of which could contribute to the negative correlation
between agr and biofilm formation. At the same time, transcription
of the genes encoding extracellular proteases, including aureolysin
(aur) and sspA, is directly repressed by both SarA and Rot [22].
Moreover, the regulatory impact of sarA, rot and agr appears to be
dependent on the relative concentrations of their products with
respect to each other rather than the concentration of any
individual product alone [50]. This suggests that USA300 isolates
may not produce extracellular proteases at the levels that might be
expected based on their relatively high overall levels of agr
expression, and we found that this was in fact the case. Specifically,
by comparison to RN6390, all three USA300 isolates produced
reduced amounts of all extracellular proteases that could be
detected using either casein or gelatin zymography (Fig. 5). In fact,
Figure 3. Impact of plasma coating on biofilm formation. Biofilm formation was assessed in UAMS-1 and each of three USA300 isolates (WT)
and their isogenic agr (A) mutants using a static microtiter plate assay with and without plasma coating. Results are shown as the mean 6 the
standard deviation of 6 replicate samples. Statistical analysis confirmed a significant difference in all strains based on the presence vs. absence of
plasma coating. No significant differences were observed between any wild-type strain and its isogenic agr mutant irrespective of whether plasma
coating was employed.
doi:10.1371/journal.pone.0010790.g003
Figure 4. Impact of sarA and agr on biofilm formation in
USA300 isolates. Biofilm formation was assessed in each of three
USA300 isolates (WT) and their isogenic sarA (S), agr (A), and sarA/agr
(SA) mutants using a static microtiter plate assay. Results are shown as
the mean 6 the standard deviation of 6 replicate samples. Statistical
analysis confirmed a significant difference between each wild-type
strain and its isogenic sarA and sarA/agr mutants but no difference
between any wild-type strains and its agr mutant or between isogenic
sarA and sarA/agr mutants.
doi:10.1371/journal.pone.0010790.g004
sarA and agr in Biofilms
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RN6390 despite the relatively low levels of RNAIII production in
UAMS-1. As was observed in assays examining the production of
RNAIII (Fig. 1), this was true whether protease production was
assessed using supernatants from cultures grown in TSB or in
biofilm medium (Fig. 5).
These results also suggest that the enhanced ability of USA300
isolates to form a biofilm by comparison to RN6390 might be a
function of their decreased production of extracellular proteases.
To further address this issue, we examined the relative impact of
mutating sarA and agr on both biofilm formation and protease
production, and in all cases we found a direct and inverse
relationship between these two phenotypes. Specifically, the only
strain derived from RN6390 that produced a biofilm in our
microtiter plate assay was an agr mutant, which also exhibited
decreased production of extracellular proteases (Fig. 6). Although
mutation of sarA in RN6390 had relatively little impact of either of
these phenotypes, concomitant mutation of sarA and agr in
RN6390 reversed both phenotypes by comparison to the
corresponding agr mutant (Fig. 6). This demonstrates that sarA is
epistatic to agr even in RN6390 in the context of both protease
production and biofilm formation. The same inverse relationships
were also observed in UAMS-1 and all three of the USA300
isolates we examined, the difference being that the impact of sarA
Figure 5. Production of extracellular proteases in USA300 isolates. Supernatants were harvested from overnight (15 hr) cultures grown in
TSB (left) or biofilm medium (right) and standardized with respect to each other prior to zymographic analysis using both casein (top) and gelatin gels
(bottom).
doi:10.1371/journal.pone.0010790.g005
Figure 6. Relationships between sarA, agr, protease production and biofilm formation. Biofilm formation and the production of
extracellular proteases was assessed in the indicated wild-type (WT) strains and their isogenic sarA (S), agr (A), and sarA/agr (SA) mutants with and
without complementation with a functional copy of sarA (S
C). Results for biofilm assay (top) are shown as the mean 6 the standard deviation of 6
replicate samples. Statistical analysis confirmed a significant difference between the RN6390 agr and sarA-complemented RN6390 sarA/agr mutants
and all other RN6390 derivative and between the sarA and sarA/agr mutants and their sarA-complemented derivatives in both UAMS-1 and UAMS-
1782. No significant differences were observed the sarA-complemented derivatives of UAMS-1 or UAMS-1782 and their respective parent strains.
doi:10.1371/journal.pone.0010790.g006
sarA and agr in Biofilms
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agr (Fig. 6). These results confirm that the impact of sarA on
protease production and biofilm formation is at least partially
independent of agr. This was confirmed by demonstrating that the
sarA defect was complemented in all strains, including RN6390, by
introducing a functional, plasmid-borne copy of sarA even into a
sarA/agr double mutant (Fig. 6).
While suggestive, the inverse relationship between biofilm
formation and the production of extracellular proteases does not
prove a cause-and-effect relationship. However, we subsequently
demonstrated that a cocktail of three protease inhibitors that is
capable of limiting the activity of multiple S. aureus extracellular
proteases [23] enhanced biofilm formation in sarA mutants
generated in UAMS-1, RN6390, and in two of the three
USA300 isolates, the only exception being the USA300 isolate
UAMS-1625 (Fig. 7). The overall levels of both RNAIII (Fig. 1)
and extracellular proteases (Fig. 8) were comparable between
UAMS-1625 and the other USA300 isolates, and the impact of
mutating sarA on the production of extracellular proteases was
comparable in all strains other than RN6390 (Fig. 8). This suggests
that one possible explanation for the differential impact of protease
inhibitors in UAMS-1625 is that this strain produces either a
unique protease that was not inhibited by any component of the
inhibitor cocktail or a common protease that is produced in
elevated amounts by comparison to the other strains such that the
inhibitor cocktail had a reduced effect in this strain. In this respect
it is important to note that the inclusion of protease inhibitors did
not fully restore biofilm formation (Fig. 7) or protease production
(Fig. 8) in any of the sarA mutants. However, the relative impact of
the inhibitor cocktail also appeared to be comparable among all
USA300 isolates including UAMS-1625 (Fig. 8).
Interestingly, while the overall impact of the inhibitor cocktail
was consistent in all strains we did observe a strain-dependent
effect with respect to both the impact of mutating sarA and the
relative efficacy of the protease inhibitor cocktail. Specifically, in
UAMS-1, the impact of mutating sarA was most evident in the
increased production of aureolysin and SspA, and the impact of
the protease inhibitor cocktail was most evident in the reduced
activity of SspA and ScpA (Fig. 8). In contrast, the impact of
mutating sarA in USA300 isolates was most evident in the
production of aureolysin, SspA and SspB, with the inhibitor
cocktail having the greatest impact on the activity of SspB. The spl-
encoded proteases have also been implicated in biofilm formation
[8], but these were not detectable in either of our zymograms.
These results are consistent with the hypothesis that multiple
proteases contribute to the biofilm-deficient phenotype of S. aureus
sarA mutants [7,8,23].
The impact of sarA on production of the polysaccharide
intercellular adhesin (PIA)
UAMS-1625 can also be distinguished from the other USA300
isolates included in this study by the absence of the arginine
catabolite metabolic element (ACME) [38]. We are unaware of a
correlation between ACME and biofilm formation, but there are
reports describing the role of the arc operon itself in this context.
Specifically expression of the arc operon was induced in UAMS-1
in a biofilm by comparison to both exponential and stationary-
phase planktonic cultures [27]. Additionally, mutation of arcD,
which encodes the arginine/ornithine antiporter of the arginine
deiminase pathway, resulted in the reduced production of PIA in
UAMS-1 [44]. However, as with the ica operon itself [27], this was
not associated with a decreased capacity to form a biofilm.
Nevertheless, the possibility that ACME contributes to biofilm
formation by virtue of its impact on the production of PIA cannot
be ruled out. Indeed, mutation of sarA results in reduced
production of PIA [7,11], and based on this one possible
explanation for our results is that PIA plays a more important
role in biofilm formation in UAMS-1625 than in the other
USA300 isolates and that, in the absence of ACME, a UAMS-
1625 sarA mutant cannot produce enough PIA to sustain biofilm
formation irrespective of any other factor including extracellular
proteases. To explore this possibility, we examined the relative
Figure 7. The impact of protease inhibitors on biofilm formation in S. aureus sarA mutants. Biofilm formation was assessed in each of the
indicated strains (WT) and their isogenic sarA mutants with (S
PI) and without (S) the inclusion of protease inhibitors. Results are shown as the mean 6
the standard deviation of 6 replicate samples. Statistical analysis confirmed a significant difference between each wild-type strain and its sarA mutant
and, with the exception of UAMS-1625, between the sarA mutants assayed in the presence or absence of protease inhibitors. In RN6390 and UAMS-
1782, the difference between the wild-type strain and its isogenic sarA mutant assayed in the presence of protease inhibitors was also significant.
doi:10.1371/journal.pone.0010790.g007
sarA and agr in Biofilms
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immunoblot. These studies demonstrated that all of the USA300
isolates produced almost undetectable amounts of PIA irrespective
of the presence of ACME or the functional status of sarA (Fig. 9).
This not only suggests that the relative levels of PIA production do
not account for the difference between UAMS-1625 and other
USA300 isolates but also that PIA plays little role in USA300
biofilm formation. This is also consistent with previous reports
demonstrating that mutation of ica had little effect on biofilm
formation not only in LAC [8] but also in other methicillin-
resistant S. aureus strains [45].
The impact of sarA on nuclease production and its
impact on biofilm formation
Overall, our results are consistent with the hypothesis that the
inability of sarA mutants to repress the production of extracellular
proteases plays a predominant role with respect to their dominant-
negative phenotype by comparison to agr. However, the inclusion
of protease inhibitors did not fully restore biofilm formation in any
of the sarA mutants (Fig. 7). One explanation for this partial effect
is that the concentration of each inhibitor, which was chosen based
on the highest concentration that did not inhibit growth [23], did
not fully inhibit the activity of all extracellular proteases in UAMS-
1 or any of the USA300 sarA mutants by comparison to their
respective parent strains (Fig. 8). The alternative although not
mutually exclusive explanation for the partial impact of protease
inhibitors is that other factors also contribute to the biofilm-
deficient phenotype of sarA mutants. Because extracellular DNA
(eDNA) also contributes to biofilm formation in S. aureus [25,26],
one possibility in this regard is the production of extracellular
nucleases. Indeed, we previously demonstrated that mutation of
sarA in UAMS-1 resulted in increased production of nuclease and
that mutation of nuc partially restored the ability of a UAMS-1 sarA
mutant to form a biofilm [23]. In this report, we found that
mutation of sarA also results in increased production of
extracellular nucleases in USA300 isolates (Fig. 10). Moreover,
the same epistatic relationships between sarA and agr that were
observed in the context of biofilm formation and protease
production were also observed in the context of nuclease
production (Fig. 11). This demonstrates that the impact of sarA
on nuclease production is also independent of the interaction
between sarA and agr and that nuclease production and biofilm
formation are also inversely correlated.
Concomitant mutation of sarA and agr resulted in increased
nuclease activity in all strains even by comparison to the isogenic
sarA mutant (Fig. 11). In this respect it is important to note that,
while protease production remained elevated in sarA/agr mutants
by comparison to the parent strains, it was reduced by comparison
to the corresponding sarA mutants (Fig. 6). Thus, one possible
explanation for these results is that the increased production of
extracellular proteases limits the accumulation of extracellular
nucleases and that the negative impact of mutating agr on protease
production attenuates this effect. Additionally, UAMS-1 and all
three isolates of the USA300 clonal lineage produced extracellular
nucleases at levels that exceeded those observed in RN6390
(Figs. 10 and 11). Given its high level of protease production by
comparison to clinical isolates, one possible explanation for this is
that the increased production of extracellular proteases also limits
nuclease activity in RN6390 irrespective of the functional status of
sarA. However, the important point is that, because RN6390 was
the only strain that did not form a biofilm even with plasma
coating, these results are an exception to the inverse relationship
between nuclease production and biofilm formation, and to the
extent that no such exceptions were observed with respect to
protease production, they are also consistent with the hypothesis
Figure 8. The impact of protease inhibitors on the activity of
extracellular proteases. Supernatants from the wild-type strains
(WT) and their isogenic sarA mutants with (S
PI) and without (S) protease
inhibitors were harvested from overnight cultures and standardized
with respect to each other prior to zymographic analysis using both
casein (top) and gelatin gels (bottom). Based on relative activity with
casein vs. gelatin, molecular size, and known polymorphisms within the
corresponding genes/proteins [49], the presumed identity of specific
proteases are SspA (1), aureolysin (2), ScpA (3) and SspB (4). The identity
of other proteases remains unknown.
doi:10.1371/journal.pone.0010790.g008
Figure 9. Role of sarA in production of the polysaccharide intracellular adhesin (PIA). PIA was isolated from each of the wild-type strains
(WT) and their isogenic sarA mutants (S) and immunoblotted using anti-PIA serum. A UAMS-1 ica mutant was included as a negative control. Upper
and lower rows are duplicate samples from each strain.
doi:10.1371/journal.pone.0010790.g009
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role by comparison to extracellular nucleases in S. aureus biofilm
formation. Moreover, RN6390 was also found to produce more
PIA than either UAMS-1 or the USA300 isolates (Fig. 9). Thus, of
the three sarA-regulated components known to contribute to
biofilm formation, RN6390 produces two (PIA and nuclease) at
levels that would be expected to promote biofilm formation and
one (protease) at levels that would be expected to limit biofilm
formation. Taken together, these results provide further support
for the hypothesis that the sarA-mediated repression of extracel-
lular proteases plays a predominant role in S. aureus biofilm
formation.
At the same time, our previous results focusing on the impact of
nuclease production on biofilm formation in UAMS-1 were done
using a mutant generated in the nuc gene designated as open-
reading frame SA0746 in the N315 genome, mutation of which
was shown to abolish nuclease production even in a UAMS-1 sarA
as assessed using DNase agar [23]. However, a recent report
demonstrated the existence of two functional nuclease genes in S.
aureus, one of which is encoded by SA0746 while the other is
encoded by SA1160 [51]. These were designated nuc1 and nuc2
respectively. In these experiments we confirmed that mutation of
nuc1 in UAMS-1 essentially eliminated the production of
extracellular nuclease even in a sarA mutant and that mutation
of nuc2 had no effect as assessed using DNase agar (Fig. 12). Even
so, mutation of either or both of these genes was shown to enhance
biofilm formation in UAMS-1 albeit to a limited degree and only
in the absence of plasma coating (Fig. 13). This was also true in a
UAMS-1 sarA mutant although in this case the effect was
statistically significant only when both nuc1 and nuc2 were mutated
and only when the assay was done with plasma coating. These
results suggest that our failure to detect a nuclease-deficient
phenotype in our nuc2 mutant may have been due primarily to our
use of a relatively insensitive assay. They also confirm that the
increased production of nucleases contributes to biofilm formation
in S. aureus at least under some circumstances and that the agr-
independent, sarA-mediated repression of extracellular nuclease
production may also be important in this regard.
Summary
Taken together, the results discussed above demonstrate that sarA
is epistatic to agr in the context of biofilm formation and that this is
true irrespective of the level of agr expression or the overall genetic
relatedness among clinical isolates. The results also suggest that the
primary regulatory role of sarA in this context is to repress the
production of extracellular enzymes including proteases and
nucleases. They also suggest that in the specific context of these
phenotypes the regulatory events observed in RN6390 reflect an
imbalance by comparison to clinical isolates including those of the
USA300 clonal lineage. This imbalance is defined both by the
absolute level of agr expression and the inability of RN6390 to
modulateexpressionofagr, and consequently the predominance of agr
relative to sarA, and this is directly reflected in the increased
production of extracellular proteases in RN6390. This presumably
reflects the fact that all 8325-4 strains, including RN6390, carry
mutations in at least two genes (rsbU and tcaR) known to impact S.
aureus regulatory circuits [22,29]. This is consistent with the
observation that restoration of rsbU in an 8325-4 strain (SH1000)
resulted in reduced production of extracellular proteases [28]. To the
extent that RN6390 was the only strain we examined in which
mutation of agr resulted in an enhanced capacity to form a biofilm
(Fig. 6), it is also consistent with the observation that the impact of
mutating agron biofilmformation in LAC was most evident in an agr/
sigB mutant [8]. Other reports have suggested that the impact of the
tcaR mutation on expression of sarS also has a profound impact on S.
Figure 10. Impact of sarA on extracellular nucleases. The
production of extracellular nucleases was assessed in the wild-type
strains (WT) and their isogenic sarA mutants using DNase agar.
doi:10.1371/journal.pone.0010790.g010
Figure 11. Epistatic relationship between sarA and agr in nuclease production. Biofilm formation and production of extracellular nucleases
was assessed using DNase agar in the indicated wild-type (WT) strains and their isogenic sarA (S), agr (A), and sarA/agr (SA) mutants with (S
C) and
without complementation of the sarA defect.
doi:10.1371/journal.pone.0010790.g011
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asp23, which is indicative of the functional status of rsbU (or, more
precisely, sigB)a n dsarS, neither of these mutations is present in any of
the clinical isolates examined in this report (Fig. 14). However, to the
extent that RN6390 has these defects, the more important
observation is that mutation of sarA resulted in a significantly reduced
capacity to form a biofilm in all of the isolates we examined other
than RN6390. Moreover, we extended our experiments to include
other clonal lineages of S. aureus, and in every case mutation of sarA
resulted in a reduced capacity to form a biofilm to a degree that was
comparable to that observed in UAMS-1 and isolates of the USA300
clonal lineage (Fig. 15).
We recently demonstrated that mutation of sarA in UAMS-1
and the USA300 isolate UAMS-1625 can be correlated with
increased antibiotic susceptibility both in vitro and in vivo [12,13],
and our results demonstrating a comparable effect in other clinical
isolates suggest that this would be the case irrespective of strain
identity. This is consistent with the hypothesis that inhibitors of
sarA-mediated regulation would have broad therapeutic utility in
the specific context of biofilm-associated staphylococcal infection.
While such inhibitors would have neither bacteriostatic or
bactericidal properties and thus would have limited therapeutic
utility in and of themselves, many S. aureus infections are
recalcitrant to antimicrobial therapy even in the absence of issues
related to acquired resistance. This includes orthopaedic and
catheter-associated infections, the resolution of which often
requires surgical intervention to debride infected tissues and/or
removal of the infected device [42,43,52,53]. Based on this, such
inhibitors would potentially be a viable alternative for the
development of adjunct therapies that could be used to
significantly enhance the efficacy of more conventional antimi-
crobial agents in the specific context of S. aureus biofilm-associated
infection. The results we report demonstrate that the impact of
sarA on biofilm formation is epistatic to agr, and this implies that,
irrespective of the specific mechanism involved, such inhibitors
would maintain their efficacy even in the context of the
accumulation of agr mutants that occurs not only within biofilms
[6] but also in vivo during the course of antimicrobial therapy [15].
Materials and Methods
Bacterial strains and growth conditions
The S. aureus strains used in this study are listed in Table 1.
Generation of agr, sarA and agr/sarA mutants in each of the
targeted strains was done by W11-mediated transduction of the
agr::tet, sarA::tet or sarA::kan mutations from existing strains [24].
Complementation of the sarA mutation was done as previously
described [24]. Mutagenesis of the SA0746-encoded nuclease gene
(designated here as nuc1) in UAMS-1 and its isogenic sarA mutant
was done using pKOR1 as previously described [7]. The UAMS-1
Figure 12. Activity of UAMS-1 nuclease genes. Nuclease activity
was assessed using DNase agar in UAMS-1 (WT) and its sarA mutant and
in derivatives of each of these strains carrying mutations in SA0746
(nuc1) and/or SA1160 (nuc2).
doi:10.1371/journal.pone.0010790.g012
Figure 13. Impact of nuclease genes on biofilm formation. Biofilm formation was assessed in UAMS-1 (WT) and its sarA mutant (S) and in
derivatives of each of these strains carrying mutations in nuc1 (n1), nuc2 (n2), or both nuc1 and nuc2 (n12) with and without plasma coating of the
substrate. Results are shown as the mean 6 the standard deviation of 6 replicate samples. Statistical analysis confirmed a significant difference
between UAMS-1 (WT) and the isogenic nuc1, nuc2 and nuc1/nuc2 mutants in the absence of plasma coating and between the sarA mutant (S) and its
isogenic nuc1/nuc2 mutant in the presence of plasma coating.
doi:10.1371/journal.pone.0010790.g013
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allele replacement mutagenesis. Specifically, 498 and 469 bp
fragments were independently amplified from the upstream and
downstream regions of the targeted gene using the primers shown
in Table 1. These fragments were cloned into pGD647 [54] on
either side of the erm gene using the EcoRI and KpnI restriction
sites for the upstream fragment and XbaI and PstI restriction sites
for the downstream fragment. The resulting nuc2-erm-nuc2
cassette, which contains all of the SA1160 gene except the
115 bp region that was replaced with the 1.3 kb erm gene, was then
excised by EcoRI/PstI digestion and subcloned into pCL52.2 [55].
After passage through RN4220 and electroporation into UAMS-1,
allele replacement was accomplished by growth and 45uC followed
by repetitive culture without antibiotic selection at 30uC. Colonies
were plated on tryptic soy agar (TSA) without antibiotic and then
patched to TSA containing erythromycin or tetracycline. Colonies
resistant to erythromycin and sensitive to tetracycline were then
screened by PCR to confirm allele replacement using the 59
Figure 14. Expression of asp23 and sarS in clinical isolates. RNA was isolated from each of the indicated strains during the exponential (E) and
post-exponential (PE) growth phases and the amounts of the asp23 and sarS transcripts determined by qRT-PCR. Values obtained with RN6390
exponential phase cultures were set to 1.0 with the results observed with other strains shown relative to this value. Results are shown as the mean 6
the standard deviation of duplicate samples. Statistical analysis confirmed a significant difference between RN6390 and each of the other strains in
the context of both asp23 and sarS during both the exponential and post-exponential growth phases.
doi:10.1371/journal.pone.0010790.g014
Figure 15. Impact of sarA on biofilm formation in isolates of other USA clonal lineages. Biofilm formation was assessed in wild-type strains
(WT) from each of eight USA clonal lineages (numerical designations refer to USA clonal lineage) and their corresponding sarA mutants (S). Results are
shown as the mean 6 the standard deviation of 6 replicate samples. Statistical analysis confirmed a significant difference between each wild-type
strain and its isogenic sarA mutant.
doi:10.1371/journal.pone.0010790.g015
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downstream PCR. The resulting nuc2 mutation was subsequently
introduced into the isogenic nuc1, sarA and sarA/nuc1 mutants by
phage-mediated transduction [7].
All strains were maintained as stock cultures at 280uC in tryptic
soy broth (TSB) containing 25% (v/v) glycerol. For each
experiment, each strain was retrieved from cold storage by plating
on tryptic soy agar (TSA) with appropriate antibiotic selection.
Antibiotics were used at the following concentrations: erythromy-
cin (Erm; 10 mg per ml), tetracycline (Tet; 5 mg per ml), kanamycin
(Kan; 50 mg per ml), neomycin (Neo; 50 mg per ml), and
chloramphenicol (Cm; 10 mg per ml). Kanamycin and neomycin
were always used together to avoid the spontaneous generation of
resistant strains. To ensure that the results of all phenotypic assays
were consistent, unless otherwise noted all assays were done using
cultures grown in TSB supplemented with 0.5% glucose and 3.0%
sodium chloride (biofilm medium) without antibiotic selection as
previously described [7,10,27]. Culture conditions in all cases were
37uC with constant aeration and a medium-to-flask volume ratio
of #0.50. In experiments evaluating the impact of growth phase,
the exponential and post-exponential growth phases were defined
based on optical densities (OD) of 1.0 and 3.0 respectively.
Stationary phase samples were defined by overnight (24 hr)
growth.
Transcriptional analysis
To assess levels of asp23, sarS and RNAIII expression, total
bacterial RNA was isolated using the Qiagen RNeasy Mini Kit as
previously described [23]. Quantitative, real-time RT-PCR (qRT-
PCR) was then performed using RNAIII-specific primers and a
corresponding TaqMan probe (Table 2). Results were calibrated
by comparison to the results obtained with the same RNA samples
using primers and a TaqMan probe corresponding to a 16S
ribosomal RNA gene (Table 2). Results are reported as relative
units by comparison to the results observed with the lowest sample
in any given experiment, with the latter being set to a value of 1.0.
Assessment of biofilm formation
Biofilm formation was assessed in vitro using a static, microtiter
plate biofilm assay as previously described [7,10]. Unless otherwise
indicated, the microtiter plate substrate was first coated overnight
with 20% human plasma.
Production of extracellular proteases
Protease activity was assessed by zymography using 4–16%
Zymogram (Blue Casein) Gels and 10% Zymogram (Gelatin) Gels
(Invitrogen, Carlsbad, CA). In both cases, supernatants were
harvested from overnight (15 hr) c u l t u r e sa n dn o r m a l i z e dw i t h
respect to each other prior to filter sterilization. Sterile supernatants
were then concentrated 15-fold using Centricon YM-3 filter units
(Millipore, Bedford, MA) before loading equivalent samples using a
buffer containing DTT but not b-mercaptoethanol. After electro-
phoresis, gels were first incubated for 30 min at room temperature
(RT) in renaturing buffer (2.5% TritonX-100) and then overnight at
37uC in developing buffer (0.2 M Tris, 5 mM CaCl2, 1 mM DTT).
Table 1. Bacterial strains used in this study.
Strain Description Reference
UAMS-1 MSSA, osteomyelitis isolate [56]
UAMS-128 RN6390 (8325-4) [57]
UAMS-155 UAMS-1agr::tetM [24]
UAMS-240 UAMS-128, sarA::tetK [24]
UAMS-929 UAMS-1, sarA::kan [24]
UAMS-930 UAMS-929, agr::tetM [24]
UAMS-959 UAMS-983, agr::tetM [24]
UAMS-969 UAMS-929, (pLI50::sarA) [24]
UAMS-970 UAMS-930, (pLI50::sarA) [24]
UAMS-979 UAMS-983, (pLI50::sarA) [24]
UAMS-980 UAMS-959, (pLI50::sarA) [24]
UAMS-982 UAMS-128, agr::tetM [24]
UAMS-983 UAMS-128, sarA::kan [24]
UAMS-1039 USA400 isolate (MW2) NRS123
1
UAMS-1454 UAMS-1 nuc2::erm This study
UAMS-1471 UAMS-1 nuc1 [23]
UAMS-1477 UAMS-929 nuc1 [23]
UAMS-1478 UAMS-1 nuc1, nuc2::erm This study
UAMS-1484 UAMS-929 nuc2 This study
UAMS-1485 UAMS-929, nuc1, nuc2::erm This study
UAMS-1625 USA300 isolate [38]
UAMS-1653 UAMS-1625, sarA::tetK [12]
UAMS-1660 UAMS-1625, agr::tetM This study
UAMS-1782 USA300 isolate FPR3757 NRS482
UAMS-1790 USA300 isolate [37]
UAMS-1796 UAMS-1790, sarA::tetK This study
UAMS-1804 UAMS-1782, sarA::kan This study
UAMS-1819 UAMS-1782, agr::tetM This study
UAMS-1820 UAMS-1790, agr::tetM This study
UAMS-1836 UAMS-1660, sarA::tetK This study
UAMS-1837 UAMS-1819, sarA::kan This study
UAMS-1838 UAMS-1820, sarA::tetK This study
UAMS-1893 USA100 isolate NRS642
UAMS-1894 USA200 isolate NRS651
UAMS-1895 USA500 isolate NRS685
UAMS-1896 USA600 isolate NRS648
UAMS-1898 USA800 isolate NRS653
UAMS-1899 USA1000 isolate NRS676
UAMS-1900 USA1100 isolate NRS484
UAMS-1901 UAMS-1804, (pLI50::sarA) This study
UAMS-1904 UAMS-1837, (pLI50::sarA) This study
UAMS-1930 UAMS-1899, sarA::kan This study
UAMS-1931 UAMS-1900, sarA::kan This study
UAMS-1938 UAMS-1039, sarA::kan This study
UAMS-1941 UAMS-1893, sarA::tetK This study
UAMS-1942 UAMS-1895, sarA::tetK This study
UAMS-1943 UAMS-1896, sarA::tetK This study
UAMS-1944 UAMS-1898, sarA::tetK This study
UAMS-1945 UAMS-1894, sarA::tetK This study
1NRS isolates were obtained from the repository at the Network for
Antimicrobial Resistance in Staphylococcus aureus (NARSA), Eurofins Medinet,
Inc., Chantilly, VA 20151.
doi:10.1371/journal.pone.0010790.t001
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SafeStain (Invitrogen, Carlsbad, CA) at RT for 2 hrs before
destaining overnight in distilled water. Assays employing the E-64,
1-10-phenanthroline (Fisher Scientific, St. Louis, MO) and dichlor-
oisocoumarin (DIC) (Sigma Chemical Co., St. Louis, MO) protease
inhibitors were done as previously described using the highest
concentration of each inhibitor that did not limit growth (4).
Production of extracellular nucleases
Nuclease production was assessed using D’NASE Test Agar
(REMEL, Lenexa, KS). Briefly, supernatants were harvested from
overnight (15 hr) cultures and normalized with respect to each
other prior to filter sterilization. Sterile supernatants were then
concentrated 15-fold Centricon YM-3 filter units (Millipore,
Bedford, MA). 15 ml aliquots were then placed into wells cut into
the D’NASE test agar. Plates were incubated overnight at 37uC.
Nuclease activity was then assessed by overlaying the agar with 1N
HCl to precipitate undigested DNA and define the zone of
clearance around the supernatant harvested from each strain.
Production of the polysaccharide intercellular adhesin
(PIA)
To assess the production of PIA, overnight cultures were
normalized with respect to each other before harvesting cells by
centrifugation. Cells were resuspended in 50 ml of 0.5 M EDTA
(pH 8.0) and boiled for 5 min. Cellular debris was removed by
centrifugation before incubating the supernatant with proteinase
K (20 mg/ml) at 37uC for 60 minutes. After the addition of 10 ml
of Tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl
[pH 7.4]), each extract was spotted onto a nitrocellulose
membrane using a BIO-Dot microfiltration apparatus (Bio-Rad
Laboratories, Inc., Hercules, CA). After drying, the presence and
amount of PIA was assessed using anti-PIA antiserum and the
WesternBreeze chemiluminescence immunodetection kit (Invitro-
gen Corp., Carlsbad, CA).
Statistical analysis
Statistical analysis of results comparing wild-type strains was
done using the Students t-test. Statistical analysis of results
comparing different strains with their isogenic sarA and agr
mutants and their sarA-complemented derivatives was done by
ANOVA based on all pairwise comparisons. In both cases p values
,0.05 were considered significant.
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